In recent years, studies have provided substantial in vivo evidence of dynamic alternation of Nrf2 expression, as well as its target genes, and cellular and subcellular distribution of Nrf2 during different stages of cerebral ischemia. The gene discussed is NFE2L2; the disease is Cerebral ischemia.